Strungmann and his brother Thomas sold two pharmaceutical companies for 5.7 billion euros ($7.5 billion) in 2005. The pair sold drugmaker Hexal as well as their 68% stake in affiliate EON Labs. The siblings, who shared the proceeds equally, invest in companies through Zurich-based Santo Holding and Munich-based Athos.
Strungmann's wealth derives from his half share of the proceeds from the sale of two pharmaceutical companies in 2005. Strungmann and his brother Thomas raised 5.7 billion euros ($7.5 billion) from the sale of generic drug maker Hexal and their 68% stake in Hexal's affiliate EON Labs.
The brothers jointly own stakes in publicly traded biotech firms. The biggest is their stake in BionTech, a company involved in the production of a Covid-19 vaccine. They own about 43% of the company based on a February 2024 regulatory filing. They also hold about 70% of 4SC and 26% of Formycon.
The value of his cash investments has been adjusted based on an analysis of dividends, taxes and market performance, and include his share of assets held in trust by Munich-based investment firm Athos.
Some of the proceeds from the sale were used to invest in startup companies through Santo Holding, which doesn't disclose financials. The Zurich-based group is valued based on the equity value of its Holzkirchen, Germany-based major subsidiary Santo Holding (Deutschland), which is published annually on the German Federal Gazette.
Santo and Athos are owned as well by the brothers' families, and their assets are attributed to Thomas and Andreas in this analysis to reflect their roles as heads of their family. The family also own Uruguayan pharmaceutical company MegaLabs, which is valued using reported financial results and the average price-to-earnings multiple of four publicly traded peers: Pfizer Inc, AstraZeneca PLC, Roche Holding AG and GSK PLC.
Hanspeter Burkhart, a spokesman for Santo Holding in Zurich, didn't respond to messages seeking comment.
Strungmann was born in early 1950 with his identical twin brother, Thomas. Both brothers obtained doctorates, Thomas in economics and Andreas in medicine.
Thomas and Andreas joined the family business Durachemie in 1979, working with their father Ernst who started it 10 years earlier. After selling the company in 1986, the brothers started Hexal, which they built into one of the world's biggest generic drug companies, according to the Ernst Strungmann Institute website.
Hexal was sold in 2005 to publicly traded pharmaceutical company Novartis. The brothers also off loaded their two-thirds stake in US generic drug company Eon Labs. The sales generated 5.7 billion euros ($7.5 billion) in cash for the brothers.
The brothers continued to work in partnership following the sales and invested more than 500 million euros in German biotechnology companies. Thomas told Germany's Manager Magazin in 2008 that he and his brother were planning to create something similar to Hexal.
In the same year, the brothers provided 200 million euros ($220 million) to establish neuroscience research group, the Ernst Strungmann Institute. It's fully-funded by the pair and named after their father.
Both brothers live near Munich.